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Abstract
Background: This study evaluates the existence of numerical alterations of chromosome 17 and
TP53 gene deletion in gastric adenocarcinoma. The p53 protein expression was also evaluated, as
well as, possible associations with clinicopathological characteristics.
Methods: Dual-color fluorescence in situ hybridization and immunostaining were performed in
twenty gastric cancer samples of individuals from Northern Brazil.
Results: Deletion of TP53 was found in all samples. TP53 was inactivated mainly by single allelic
deletion, varying to 7–39% of cells/case. Aneusomy of chromosome 17 was observed in 85% of
cases. Chromosome 17 monosomy and gain were both observed in about half of cases. Cells with
gain of chromosome 17 frequently presented TP53 deletion. The frequency of cells with two chr17
and one TP53 signals observed was higher in diffuse than in intestinal-type GC. Immunoreactivity
of p53 was found only in intestinal-type samples. The frequency of cells with two chr17 and two
TP53 signals found was higher in samples with positive p53 expression than in negative cases in
intestinal-type GC.
Conclusion: We suggest that TP53 deletion and chromosome 17 aneusomy is a common event
in GC and other TP53 alterations, as mutation, may be implicated in the distinct carcinogenesis
process of diffuse and intestinal types.
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Gastric cancer (GC) is the fourth most frequent malig-
nancy and the second most common cause of cancer
death in the World [1]. In the State of Pará (Northern Bra-
zil), GC was the most common cause of cancer death in
2000. In Belém, State of Pará, the 5-year-survival rate is
about 9–10% [2]. A better understanding of the biology of
this neoplasia progression is crucial for the development
of better tests to early neoplasia detection and also of new
treatment strategies for GC.
Molecular events in the carcinogenesis of GC remain
largely unknown [3]. A key feature in the pathogenesis of
most GC, as in many other solid cancers, is chromosomal
instability, resulting in gains and losses of parts or even
whole chromosomes [4].
Gastrointestinal tract tumors are notorious for being diffi-
cult to be analyzed by standard cytogenetic techniques [5-
9]. Fluorescence in situ hybridization (FISH) assay allows
rapid detection of numerical genetics aberrations in inter-
phase nuclei in tumor cells. FISH assay should be used to
evaluate cell-to-cell heterogeneity in gene or loci copy
number and detect small subpopulations of genetically
aberrant cells [10]. FISH studies have shown numerical
aberrations 1, 7, 8, 9, 17, 20, X and Y to be common in GC
[[7,11-19], see also review [20]]. There are some studies in
literature concerning TP53, located at chromosome
17p13.1, and chromosome 17 (chr17) copy number alter-
ations by FISH assay in GC [[21-24], see also review [20]].
The TP53 tumor suppressor plays a pivotal role in the
coordination of the repair process or in the induction of
apoptosis. TP53 somatic alteration is described in approx-
imately 50% of human cancers, including GC [25]. Dereg-
ulation of the TP53 pathway has been shown to involve
mutations, loss of heterozygosity (LOH), increased
expression of the TP53 inhibitor HDM2, or epigenetic
silencing of the TP53 promoter [26,27].
The aim of this study was to investigate chr17 and TP53
numerical alterations in GC samples from Pará State by
dual-color FISH technique. Immunostaining for p53 pro-
tein was also evaluated. These results were correlated with
clinicopathological characteristics.
Methods
Samples
The study included 20 gastric adenocarcinoma samples.
Samples of primary tumors submitted to surgical resec-
tion were obtained from João de Barros Barreto University
Hospital (HUJBB). This study investigated cancer samples
of patients from Pará State, where there is a mixed popu-
lation composed of three main ethnic groups: Amerin-
dian, African and European [28].
Patients' age, sex and tumor anatomical sites were
obtained from tumor registries. The mean age of the
twenty patients was 55 ± 14.67 years (range 24–77). The
female/male ratio was 3:2. All samples were classified
according to Laurén [29] and tumors were staged using
standard criteria by TNM staging [30]. According to Lau-
rén's classification, 6 were diffuse type (30%) and 14 were
intestinal type (70%). Table 1 shows cases with their his-
topathological characteristics.
All patients had negative histories of exposure to either
chemotherapy or radiotherapy prior to surgery; there was
no other diagnosed cancer. An informed consent with
approval of the ethics committee of HUJBB was obtained
from the studied patients.
Fish
FISH was applied on cells fixed in methanol/acetic acid
using recently made slides according to modified proto-
cols [31]. The slides were washed in 2× saline sodium cit-
rate (SSC)/0.5% NP-40 (pH 7.0) solution and dehydrated
in 70%, 80% and 95% ethanol. To determine the chr17
and TP53 copy numbers, cells were hybridized with 10 μL
dual-color direct labeled probe (Qbiogene®, CA, USA)
specific for chr17 α-satellite and TP53 gene region, labeled
with fluorescein and rhodamine respectively. The probe
applied to the slide under a glass coverslip. The probe and
sample were denatured at 75°C for 5 minutes and. In situ
hybridization occurred at 37°C in a moist chamber over-
night. Post-hybridization washings were done and the
nuclei were counterstained with DAPI/antifade. Molecu-
lar cytogenetic analysis was carried out under an Olympus
BX41 fluorescence microscope with triple DAPI/FITC/
TRICT filter (Olympus, Japan) and the FISHView® of
Applied Spectral Imaging® image analysis system (ASI
Ldt., Israel). For each case, 200 interphase/metaphase
nuclei were analyzed and were scored using the Hopman's
criteria [32]. In our study, the cut-off level for interphase-
FISH was 5%. To avoid misinterpretation due to technical
error, gastric mucosal tissue (nonneoplastic) and normal
lymphocyte nuclei were used as negative control.
Immunohistochemical staining
Deparaffinized tissue sections (4 μm) were incubated
with primary monoclonal antibody p53 (DO-7, dilution
1:50, DakoCytomation, CA, USA) and secondary anti-
body followed by streptavidin-biotin-peroxidase complex
(DakoCytomation, CA, USA) as previously described
[18]. Slides were visualized with diaminobenzidine-H2O2
and counterstained with Harry's hematoxylin. The results
were interpreted using the Ozturk's et al. criteria [33]. Pos-
itive p53 expression was defined as clear nuclear staining,
whereas negative p53 immunostaining was considered
when no positive cell was seen or rare cells were stained
(less than 10% weakly stained tumor cells). A breast ade-Page 2 of 7
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was used as positive control and a normal gastric mucosa
as negative control. Two pathologists evaluated the
immunostaining results independently.
Statistical analyses
Statistical analyses were performed using Fisher's exact
test and Mann-Whitney test. P value < 0.05 was consid-
ered to be statistically significant.
Results
FISH
Lymphocyte nucleus and normal gastric mucosa showed
two signals to chr17 and TP53 in 97.5% and 96.5% of
analyzed cells respectively. All cancer samples presented
numerical alterations of chr17 and TP53 gene. Normal
nuclei were observed in 50.7–88% of cells/case (Table 1).
The main TP53 alteration observed was the single allelic
deletion. This alteration was present in all cases, varying to
7–39% of cells/case (Figure 1A). Chr17 monosomy
observed in 45% of samples, ranging 5–12% of cells/case.
Chr17 gain was also detected in 45% of cases. Chr17 tri-
somy was observed in 20% of the cases in a frequency up
to 7.5% cells/case (case 19), in which 40% and 60% of
these cases showed two and one single TP53 copy number
respectively. Chr17 tetrasomy with two TP53 signals was
detected in 35% of cases in a frequency up to 9% cells/
case. Four signals to chr17 and TP53 was observed in one
case (case 2) in 13.5% of cells (Table 1).
The frequency of cells with two chr17 and one TP53 sig-
nals observed was higher in diffuse than in intestinal-type
GC (p = 0.026). Chromosome alterations were not associ-
ated with other clinicopathological characteristics.
p53 protein expression
In the present study, breast adenocarcinoma (positive
control) showed p53 overexpression and the normal gas-
tric mucosa (negative control) showed lack of p53 immu-
noreactivity.
Seventeen GC samples were analyzed by immunostain-
ing. Immunoreactivity of p53 (positive) was found in 8
cases (47%) (Figure 1B). All of these cases were intestinal-
type (8 of 12 samples). Statistical analysis showed an
association between intestinal-type GC and p53 expres-
sion (p = 0.0294). In our sample, p53 immunoreactivity
was not associated with age, gender, location and TNM
status (p > 0.05) (Table 1).
The frequency of cells with two chr17 and one TP53 sig-
nals observed was higher in samples with immunoreactiv-
ity of p53 negative than in cases with positive p53
expression (p = 0.016). In intestinal-type GC, the fre-
quency of cells with two chr17 and two TP53 signals
Table 1: Clinicopathological, immunohistochemistry and FISH results of GC samples.
FISH chr17/TP53 (%)
Case Age Sex Loc† pTNM‡ LC§ IHC 2/2 2/1 1/1 3/2 3/1 3/3 4/2 4/1 1/2 2/3 4/4 4/3 5/4 2/4
1 77 M An T2N1Mx Int + 77.5 11.0 10.0 1.0 - 0.5 - - - - - - - -
2 48 F An T4N0Mx Int - 52.2 16.0 4.1 1.2 2.4 0.6 8.2 - - - 13.5 1.8 - -
3 58 M Co/an T1N1Mx Int + 68.5 14.5 4.5 - 3.0 - 3.5 2.5 1.5 0.5 - 1.5 - -
4 48 F Co/an T3N0Mx Int + 62.2 15.6 10.0 3.2 0.5 - 6.5 1.0 - 0.5 0.5 - - -
5 24 F Co/an T3N3Mx Int - 50.7 39.0 9.6 - - - - - 0.7 - - - - -
6 71 F An/py T2N0Mx Dif - 65.0 20.0 12.0 1.0 - 2.0 - - - - - - - -
7 41 F Co/an/py T4NxMx Int + 84.5 7.8 6.5 - - 0.6 0.6 - - - - - - -
8 63 F Co/an T4N3M1 Dif 0 67.0 25.0 3.0 2.0 - 1.0 - - - - 1.5 - - 0.5
9 68 F An T1N1Mx Int + 70.0 11.5 4.5 3.0 2.0 - 4.0 1.5 1.0 0.5 2.0 - - -
10 76 M An/py T3N1M1 Int - 68.0 14.0 2.0 2.0 6.0 - 5.0 0.5 2.5 - - - - -
11 41 F All T3N1M0 Dif - 54.5 29.5 - 2.0 3.5 - 9.0 0.5 0.5 0.5 - - - -
12 60 M An T3N2Mx Int 0 88.0 7.0 5.0 - - - - - - - - - - -
13 65 M Ca/fu T3N1Mx Int 0 69.0 16.0 10.5 - 0.5 2.0 1.0 0.5 - - - - 0.5 -
14 52 M Co/ca T2N1Mx Int + 76.5 15.0 7.5 - - 0.5 0.5 - - - - - - -
15 48 M Co/an T2N1Mx Intl + 54.0 24.0 1.5 5.0 5.5 2.5 6.0 1.5 - - - - - -
16 52 F An/py T3N1Mx Int - 53.4 27.0 1.6 3.2 4.2 1.6 8.0 - - 1.0 - - - -
17 50 F An/py T4N1Mx Int + 63.0 19.0 4.0 2.0 0.5 1.0 7.5 - 2.0 1.0 - - - -
18 47 F An T2N0Mx Dif - 65.0 17.5 9.5 1.0 2.5 1.5 1.5 1.0 - - 0.5 - - -
19 74 F Co/an/py T4N1Mx Dif - 67.0 21.5 - 1.0 7.5 - 1.5 1.5 - - - - - -
20 31 M Co/an/py T3N1Mx Dif - 62.7 24.3 2.7 5.5 1.6 - 2.7 0.5 - - - - - -
† Tumor location: An = antrum; Ca = cardia; Co = corpus; Fu = fundus; Py = pylorus | ‡ TNM pathological staging | §Laurén's classification: Int = 
Intestinal; Dif = Diffuse | Immunostaining: 0 = not done; (-) without immunoreactivity; (+) with immunoreactivity.Page 3 of 7
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Cells submitted to FISH (A) and immunohistochemistry (B) assaysFigure 1
Cells submitted to FISH (A) and immunohistochemistry (B) assays. A1 (case 14), A2 (case 5) and A3 (case 6): inter-
phase nuclei presenting chr17 monosomy (green signal) with one copy of TP53 (red signal), and nuclei presenting chr17 disomy 
with one or two copies of TP53 – 1000× magnification; B1 (case 14) and B2 (case 17): tissue with nuclear p53 immunoreactivity 
(brown stain) – 400× and 100× magnification, respectively; B3 (case 6): tissue without p53 immunoreactivity – 400× magnifica-
tion.
BMC Gastroenterology 2009, 9:55 http://www.biomedcentral.com/1471-230X/9/55found was higher in samples with positive p53 expression
than in negative cases (p = 0.027).
Discussion
Aneusomy is one of the most common findings in human
cancer. Chromosome copy number changes encompass a
continuum ranging from sporadic events to a change of
chromosome numbers with each cell division. Although
aneusomy can be detected at early stages of transforma-
tion and even in certain premalignant lesions, the degree
of numerical chromosomal aberrations generally
increases with tumor progression, and tumors with
aggressive clinical behavior are more likely to be aneu-
somy than less malignant tumors. Aneusomy has also
been found to be associated with poor treatment outcome
in cancer patients [34].
Regarding chr17 and TP53 copy number, we observed
normal nuclei in 50.7–88% of cells/case. This result cor-
roborates our previous conventional and molecular
cytogenetic studies, which demonstrated that chr17 aneu-
somy is not a frequent in GC samples of individual from
Northern Brazil [7,35,36].
There are few studies in literature concerning chr17 and
TP53 copy number alterations. Our findings corroborated
Kobayashi et al. [21] that found deletion of TP53 in 39%
of 67 tumors and all of these samples showed chr17 poly-
somy. Takahashi et al. [22] also observed that p53 signal
count was lower than the chromosome 17 signal count in
1 of 3 intestinal-type GC.
Gomyo et al. [23] demonstrated 3 or 4 signals for chr17 in
46% of 13 intestinal-type GC samples and 77% of these
cases showed TP53 deletion by FISH assay. In our sample,
45% of all cases presented 3 or 4 signals for chr17 and
TP53 deletion was detected in all cases.
Suzuki et al. [24] observed an increased of chr17 polys-
omy frequency and the incidence of TP53 deletion ranged
from 55% to 90% in ten GC samples. They also described
that TP53 deletion was significantly higher in intestinal
than in diffuse-type cancers. However, in our sample we
found TP53 deletion in up to 49% cells/case and the fre-
quency of cells with two chr17 and one TP53 signals
observed was higher in diffuse than in intestinal-type GC.
Inconsistencies regarding the frequency of TP53 deletion
in GC between our study and Suzuki et al. [24] may be
suggestive of distinct gastric carcinogenesis pathways in
different ethnic composition or differences in stage when
the analysis was done. It is widely reported that differ-
ences between carcinogenesis processes can be the result
of distinct environmental and genetic factors.
Suzuki et al. [24] also observed that chr17 monosomy was
present in 70% of 10 cases and the most frequent pattern
in these cases was the combination of one copy of chr17
and one of TP53. On the other hand, in our sample we
observed chr17 monosomy in 45% of 20 cases (cut-off
level of 5%) and the more frequent pattern was the com-
bination of two copies of chr17 with one TP53 copy by
cell.
In the present study, chr17 tetrasomy with two TP53 sig-
nals was frequently observed. We also could observe that
chr17 gain tended to be more frequently found in tumors
with higher extension (T3 or T4 stages). This finding sug-
gests that tetrasomy event is a subsequent step after gene
deletion, which could justify the higher frequency of cells
with two copies of chr17 and one TP53 copy and also the
tendency of increased level of chr17 gain in tumors with
higher extension. Galipeau et al. [37] suggested that
increased polysomy level is associated with inactivation of
the TP53 in Barrett's esophagus in vivo, supporting our
hypothesis.
Williams et al. [38] described that TP53 deletion was the
most common aberration in gastritis, intestinal metapla-
sia, dysplasia e GC by FISH assay. The author suggested
that this abnormality may exist in the initiation and pro-
gression to gastric cancer.
TP53 deletion, as well as chromosome 17 aneusomy, was
observed in all analyzed samples, despite Laurén's his-
topathologic types. However, differential p53 expression
was detected between these groups.
Increased immunostaining of p53 can depend on either
increased synthesis of wild-type protein or accumulation
of mutated protein in the cell, since the antibody recog-
nizes both types of the protein [39]. In the present study,
we observed an increased frequency of immunostained
nuclei and the greater staining intensity in 47% of GC
samples, as compared to normal gastric mucosa. We sug-
gest that the p53 overexpression may be related to the
mutated type of this protein. The frequency of p53 overex-
pression in GC has been described varying from 19% to
57.5% of cases [23,40-44] and some studies also
described TP53 mutations related with its protein overex-
pression [23,41].
In the present study, only intestinal-type GC presented
p53 immunoreactivity. Our research suggests that, beside
TP53 loss by allelic deletion or chr17 aneusomy, a muta-
tion in the remaining TP53 allele may exist in intestinal-
type GC samples, which would explain the protein immu-
noreactivity. On the other hand, two possibilities might
be considered to the absence of immunoreactivity in dif-
fuse-type GC: this absence was not due to mutations inPage 5 of 7
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interfere in the protein accumulation. In both situations
the immunoreactivity cannot be detected.
The p53 expression was also associated with a higher fre-
quency of cells with two chr17 and two TP53 signals in
intestinal-type GC. We hypothesize that these cells may
present TP53 with mutations and this event could be
occurring earlier than allelic deletion in intestinal-type
gastric carcinogenesis. Further investigations concerning
TP53 mutations and expression should be done in larger
samples, also including early GC specimens.
Conclusion
Our findings showed that TP53 deletion and chromo-
some 17 aneusomy are common events in GC. Our results
also suggest that LOH is an important TP53 alteration in
GC. However, other TP53 alterations than allelic deletion
may be implicated in the carcinogenesis process.
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